Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1(E17K)-Mutant, ER-Positive Metastatic Breast Cancer

PURPOSE: The activating mutation AKT1(E17K) occurs in ~7% of ER+ metastatic breast cancer (MBC). We report, from a multipart, first-in-human, Phase I study (NCT01226316), tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy or combined with fulvestrant in expansion cohort...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Smyth, Lillian M., Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva, Mayer, Ingrid A., Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen, Ashton, Jack, Barnicle, Alan, Cashell, Des, Corcoran, Claire, de Bruin, Elza C., Foxley, Andrew, Hauser, Joana, Lindemann, Justin P.O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S., Chandarlapaty, Sarat, Baselga, José, Hyman, David M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415507/
https://ncbi.nlm.nih.gov/pubmed/32312891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3953
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky